Last updated: August 24, 2026
Omeprazole and sodium bicarbonate is a mature, low-growth proton-pump inhibitor combination marketed primarily as Zegerid and generic equivalents. The product has limited remaining exclusivity, no biosimilar exposure, extensive generic and OTC competition, and low strategic value relative to newer gastroesophageal reflux disease therapies. Public filings do not separately disclose product revenue, so the financial trajectory is best assessed through regulatory status, market structure, pricing pressure, and portfolio ownership rather than reported brand sales.
What is omeprazole and sodium bicarbonate?
Omeprazole and sodium bicarbonate is an immediate-release formulation combining the proton-pump inhibitor omeprazole with sodium bicarbonate. The bicarbonate raises gastric pH and protects omeprazole from acid degradation before absorption.
The principal prescription product is Zegerid, originally developed and commercialized by Santarus. The U.S. Food and Drug Administration approved prescription Zegerid under NDA 021636 in 2004. The approved prescription strengths included:
| Product |
Strength |
Dosage form |
Primary use |
| Zegerid |
20 mg omeprazole / 1,100 mg sodium bicarbonate |
Capsule |
GERD and acid-related disorders |
| Zegerid |
40 mg omeprazole / 1,100 mg sodium bicarbonate |
Capsule |
GERD and acid-related disorders |
| Zegerid |
20 mg omeprazole / 1,680 mg sodium bicarbonate |
Powder for oral suspension |
Prescription acid suppression |
Omeprazole is also sold widely as a standalone prescription and OTC product under brands including Prilosec and multiple private-label generics. The combination therefore competes against both other omeprazole products and alternative proton-pump inhibitors such as esomeprazole, lansoprazole, pantoprazole, and rabeprazole.
What patents protect omeprazole and sodium bicarbonate?
The historical patent estate focused on the immediate-release combination, the use of sodium bicarbonate as an alkalizing agent, and dosage-form claims. Patent protection has largely expired or ceased to create a meaningful barrier to generic entry.
The principal commercial protection categories were:
| Protection category |
Commercial purpose |
Current significance |
| Omeprazole plus sodium bicarbonate composition claims |
Protected the combined active ingredients and alkaline buffer |
Largely expired |
| Immediate-release dosage-form claims |
Distinguished the product from delayed-release omeprazole formulations |
Limited after generic approvals |
| Powder-for-suspension claims |
Covered reconstitutable oral products |
Limited and formulation-specific |
| Method-of-use claims |
Covered treatment of GERD and acid-related conditions |
Weak because indications are broad and clinically crowded |
| Manufacturing and processing claims |
Addressed stability, granulation, blending, and dosage-form production |
Potentially relevant only to specific processes |
Historical patent records associated with the Zegerid product included U.S. patents covering omeprazole/alkaline-buffer compositions and related pharmaceutical formulations. Patent scope varied by strength and dosage form. The key commercial point is that generic manufacturers obtained FDA approval for equivalent omeprazole and sodium bicarbonate products, demonstrating that the remaining patent estate did not block market entry.
Current freedom-to-operate analysis should distinguish:
- The active ingredient combination.
- The specific strength.
- Capsule versus powder dosage form.
- Immediate-release versus delayed-release release profile.
- Any unexpired process or formulation claims.
- The labeling used by a generic applicant.
A patent that covers a manufacturing step may have little practical value if a generic manufacturer can use a non-infringing process. A method-of-use patent may also have limited commercial effect where physicians prescribe the product for multiple routine acid-suppression indications.
When did omeprazole and sodium bicarbonate lose exclusivity?
The product lost meaningful commercial exclusivity in stages rather than on a single date.
| Event |
Approximate timing |
Market effect |
| FDA approval of prescription Zegerid |
2004 |
Established the branded prescription market |
| Introduction of OTC Zegerid |
Mid-2000s |
Expanded consumer access and increased price competition |
| Expiration of early formulation and composition protection |
Late 2010s to early 2020s |
Removed the primary patent barrier |
| Generic approvals and broad pharmacy distribution |
2010s onward |
Accelerated price erosion |
| Mature OTC and private-label competition |
2020s |
Reduced brand pricing power |
The practical loss of exclusivity occurred when generic omeprazole/sodium bicarbonate products became available and payers stopped treating Zegerid as a differentiated product. The product now operates in a mature market where therapeutic substitution is straightforward.
FDA regulatory exclusivity is separate from patent exclusivity. Any original new-drug exclusivity associated with NDA 021636 expired many years ago. The product does not have orphan-drug exclusivity, pediatric exclusivity, or other current regulatory protection that would materially delay generic competition.
What is the Orange Book status of Zegerid?
Zegerid was approved as a prescription drug under NDA 021636. FDA Orange Book analysis for the product must be performed by strength and dosage form because listed patents and approval status can differ across capsules and powder formulations.
The relevant regulatory status is:
- Active ingredient: omeprazole and sodium bicarbonate.
- Reference product: Zegerid.
- NDA holder history: Santarus and subsequent successor companies.
- Regulatory pathway for generics: ANDA approval.
- Current exclusivity: none of commercial significance.
- Small-molecule status: yes.
- Biosimilar pathway: not applicable.
Zegerid OTC products are regulated separately from the prescription NDA and have been marketed through the OTC monograph and product-specific regulatory framework. OTC status does not restore prescription patent exclusivity.
FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, remains the controlling source for current reference-product, patent-listing, and therapeutic-equivalence information. FDA’s Drugs@FDA database provides the underlying approval history and labeling records. [1,2]
Which companies have challenged or competed with Zegerid?
The commercial challenge has come primarily from generic manufacturers and private-label OTC suppliers rather than from a single high-profile Paragraph IV litigation campaign.
Potential and actual competitors include:
- Generic drug manufacturers selling omeprazole and sodium bicarbonate capsules or powders.
- Private-label retailers selling equivalent acid-reduction products.
- Manufacturers of standalone omeprazole.
- Makers of esomeprazole, lansoprazole, pantoprazole, and rabeprazole.
- Retail brands such as Prilosec OTC and competing PPI products.
- H2-receptor antagonist products such as famotidine.
The product has not faced biosimilar competition because biosimilars apply to biological products, while omeprazole and sodium bicarbonate are chemically synthesized small molecules.
What Paragraph IV challenges and patent litigation affect Zegerid?
Publicly visible market conditions indicate that generic entry has already occurred, reducing the relevance of any future Paragraph IV challenge. A Paragraph IV certification is most important before patent expiry, when a generic applicant seeks approval by alleging that a listed patent is invalid, unenforceable, or not infringed.
For omeprazole and sodium bicarbonate:
- Generic competition has already established market access.
- No active patent dispute appears to preserve a meaningful branded monopoly.
- The economic value of new Paragraph IV litigation is low.
- Any remaining dispute would likely concern a narrow dosage form, manufacturing process, or formulation claim.
- Litigation risk is more relevant to a specific ANDA applicant than to the market as a whole.
A complete litigation review should cover the FDA Paragraph IV certification database, federal district court dockets, Federal Circuit decisions, and successor-company records for Santarus, Salix Pharmaceuticals, Valeant Pharmaceuticals, and Bausch Health. The commercial consequence of historical litigation is limited because the combination is already a genericized product.
What formulations are protected by omeprazole and sodium bicarbonate patents?
The technically differentiated formulation is immediate-release omeprazole protected from gastric acid by a sodium bicarbonate buffer. Conventional omeprazole products typically use enteric-coated or delayed-release technology. This difference created the original product rationale.
Immediate-release capsules
The capsule formulation combines omeprazole with sodium bicarbonate in a solid dosage form. The main technical issues are:
- Maintaining omeprazole stability.
- Providing sufficient alkalinity.
- Controlling moisture exposure.
- Achieving uniformity between the active ingredient and buffer.
- Preserving dissolution and absorption characteristics.
Powder for oral suspension
The powder product introduces additional formulation concerns:
- Reconstitution stability.
- Dose uniformity after mixing.
- Palatability.
- Container-closure protection.
- Shelf life after reconstitution.
- Manufacturing controls for a high bicarbonate load.
Generic formulation barriers
The technical barrier is moderate rather than high. Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway, but they do not need to reproduce the branded manufacturing process. The presence of sodium bicarbonate can create formulation and stability work, yet it does not create a biologic or device-level manufacturing barrier.
How strong is the patent estate for omeprazole and sodium bicarbonate?
The patent estate is weak from an investment or licensing perspective.
| Factor |
Assessment |
| Core composition protection |
Expired or commercially exhausted |
| Method-of-use protection |
Limited value because indications are broad |
| Formulation differentiation |
Moderate technical complexity, low exclusivity value |
| Manufacturing know-how |
Replicable by established generic manufacturers |
| Regulatory exclusivity |
None of commercial significance |
| Biosimilar barrier |
Not applicable |
| Litigation leverage |
Low |
| Licensing value |
Low unless tied to a differentiated delivery system |
The remaining opportunity would involve a new formulation, such as a lower-sodium product, pediatric dosage form, modified-release system, combination with another active ingredient, or a formulation with improved tolerability. Such a product would need to create a clinically meaningful advantage because generic price competition is severe.
What is the financial trajectory of omeprazole and sodium bicarbonate?
The financial trajectory is mature-to-declining for the branded prescription product and stable-to-low-growth for the broader active-ingredient market.
Brand economics
The branded product has experienced the standard sequence for an older small-molecule drug:
- Initial prescription growth after approval.
- Expansion through OTC availability.
- Generic entry and formulary substitution.
- Declining branded volume and pricing.
- Increasing dependence on retail recognition, distribution, or private-label economics.
Santarus generated substantial value from its gastrointestinal portfolio before its acquisition by Salix Pharmaceuticals in 2014. Salix was later acquired by Valeant Pharmaceuticals, now Bausch Health. Product-level Zegerid revenue is not separately reported in current public filings, which prevents a reliable standalone revenue series. [3,4]
Market economics
The broad omeprazole category remains commercially important because GERD and acid-related conditions are common. The omeprazole/sodium bicarbonate combination captures a narrower segment than standalone omeprazole.
Economic characteristics include:
- Low average selling prices after generic entry.
- High substitution risk.
- Limited brand loyalty in prescription channels.
- Retail demand that is sensitive to shelf placement and price.
- Modest manufacturing complexity.
- Limited potential for premium pricing without clinical differentiation.
The combination can generate recurring generic revenue because PPIs are widely used, but individual manufacturers face rapid price competition and pharmacy-benefit-management pressure.
What revenue exposure exists for manufacturers?
Revenue exposure is asymmetric.
| Stakeholder |
Exposure |
| Original innovator |
Historical revenue erosion after generic entry |
| Current brand owner |
Low strategic value unless the brand retains OTC recognition |
| Generic manufacturers |
Volume opportunity with narrow margins |
| Retailers |
Private-label margin opportunity |
| API suppliers |
Stable demand but low differentiation |
| Contract manufacturers |
Moderate recurring volume, limited pricing power |
| Payers |
Low-cost treatment option |
| Investors |
Limited patent-driven upside |
The combination is unlikely to be a material growth driver for a diversified pharmaceutical company. Its value is more likely to appear in a generic portfolio, an OTC portfolio, or a broader gastrointestinal product bundle.
How does omeprazole and sodium bicarbonate compare with competing drugs?
| Product category |
Differentiation |
Patent position |
Pricing power |
Competitive risk |
| Omeprazole/sodium bicarbonate |
Immediate-release buffered formulation |
Mature and largely expired |
Low |
High |
| Delayed-release omeprazole |
Established PPI therapy |
Mature and genericized |
Low |
High |
| Esomeprazole |
Enantiomer of omeprazole |
Mature and genericized |
Low to moderate by brand |
High |
| Pantoprazole |
Delayed-release PPI |
Mature and genericized |
Low |
High |
| Lansoprazole |
Delayed-release PPI |
Mature and genericized |
Low |
High |
| Potassium-competitive acid blockers |
Newer mechanism in some markets |
Potentially stronger for newer products |
Higher |
Lower initially |
| Famotidine |
H2-receptor antagonist |
Mature and genericized |
Low |
High |
The combination’s main differentiation is formulation behavior, not superior pharmacology. That distinction is insufficient to sustain a premium once generic equivalents and alternative PPIs are broadly available.
What generic launch scenarios exist?
Base case
Generic suppliers maintain market access, prices remain compressed, and the product continues as a low-cost niche formulation. Brand demand persists mainly through consumer recognition and prescriber familiarity.
Downside case
Retailers substitute private-label products, prescription utilization shifts to standalone omeprazole or other PPIs, and manufacturers exit because of low margins or supply-chain costs.
Upside case
Demand benefits from continued use of immediate-release buffered omeprazole in patients who prefer or require the dosage form. The upside remains volume-driven rather than price-driven.
A new generic entrant would likely face limited barriers to FDA approval but significant commercial barriers after approval. Pharmacy contracting, wholesaler access, manufacturing scale, and reliable supply are more important than patent clearance.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are manageable but not negligible. Sodium bicarbonate creates a high-load excipient environment, while omeprazole is sensitive to acid and moisture. Commercial manufacturers must control:
- Raw-material quality.
- Blend uniformity.
- Moisture ingress.
- Packaging performance.
- Stability under distribution conditions.
- Powder reconstitution characteristics.
- Bioequivalence performance.
These requirements can delay development or create batch failures, but they do not provide the durable barrier associated with sterile injectables, complex biologics, inhalation devices, or highly specialized delivery systems.
The strongest residual intellectual-property opportunity would be a clearly differentiated product with a new clinical or patient-use advantage. Standard omeprazole/sodium bicarbonate products have limited prospects for patent-based price protection.
What licensing deals affected the product?
The product’s commercial history is associated with Santarus’s gastrointestinal portfolio and subsequent corporate transactions involving Salix Pharmaceuticals, Valeant Pharmaceuticals, and Bausch Health. Those transactions transferred broader corporate portfolios rather than creating a durable new patent moat for omeprazole and sodium bicarbonate.
No current high-value licensing structure is evident from public disclosures that would materially change the product’s competitive position. The product is best treated as a mature commercial asset rather than a platform for significant royalty growth.
Key Takeaways
- Omeprazole and sodium bicarbonate is a mature small-molecule PPI combination marketed principally as Zegerid and generic equivalents.
- Prescription Zegerid was approved under FDA NDA 021636 in 2004.
- Core composition and formulation protection is expired or commercially exhausted.
- No biosimilar risk exists because the product is not biologic.
- Generic and OTC competition is the principal market force.
- Public filings do not separately disclose current Zegerid revenue.
- Financial value is concentrated in recurring low-cost volume, not patent-protected pricing.
- Manufacturing complexity is moderate and does not create a durable barrier to generic entry.
- Any commercial upside would require a differentiated formulation or delivery system.
- The product has low patent-driven licensing and litigation value.
FAQs
Is omeprazole and sodium bicarbonate still protected by patents?
The original commercial protection has largely expired or lost practical value because FDA-approved generic products are available. Narrow process or formulation patents may still require claim-by-claim review.
Is Zegerid a biologic drug?
No. Zegerid contains chemically synthesized omeprazole and sodium bicarbonate. Generic applicants use the ANDA pathway rather than the biosimilar pathway.
Can a company launch a generic Zegerid product?
A company can pursue an ANDA for an approved reference product, subject to FDA requirements, patent certifications, bioequivalence, manufacturing compliance, and commercial supply capability.
Does sodium bicarbonate make Zegerid clinically superior to standard omeprazole?
The combination creates an immediate-release buffered formulation, but it does not establish broad clinical superiority over all delayed-release PPI products. Product selection depends on indication, formulation preference, patient response, and prescribing practice.
Is omeprazole and sodium bicarbonate an attractive pharmaceutical licensing target?
It has limited licensing attractiveness as a conventional genericized product. A stronger opportunity would require a new formulation, reduced sodium exposure, pediatric application, differentiated delivery technology, or another protectable clinical advantage.
References
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Bausch Health Companies Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Salix Pharmaceuticals, Ltd. (2014). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
